RGNX logo

REGENXBIO Inc. (RGNX)

$7.32

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RGNX

Market cap

$484017432

EPS

-3.21

P/E ratio

--

Price to sales

3.05

Dividend yield

--

Beta

1.238543

Price on RGNX

Previous close

$7.64

Today's open

$7.59

Day's range

$7.30 - $7.82

52 week range

$5.46 - $16.19

Profile about RGNX

CEO

Curran Simpson

Employees

371

Headquarters

Rockville, MD

Exchange

Nasdaq Global Select

Shares outstanding

66122600

Issue type

Common Stock

RGNX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RGNX

REGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

REGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 13, 2026

news preview

REGENXBIO Q3 Earnings Call Highlights

REGENXBIO NASDAQ: RGNX is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company's third-quarter earnings call.

news source

MarketBeat • Nov 6, 2026

news preview

Regenxbio: 2 Major Catalysts Could Change The Investment Case

Regenxbio Inc. is Buy-rated, with upcoming ATMOSPHERE and ASCENT readouts and RGX-202 regulatory milestones as key near-term catalysts. RGNX faces a structural revenue headwind from ZOLGENSMA royalty expiration, with new assets like ITVISMA and external funding supporting liquidity. Pivotal wet AMD Phase III data for sura-vec in 4Q26 and an RGX-202 BLA submission in 1Q27 are critical for future valuation.

news source

Seeking Alpha • Nov 6, 2026

news preview

REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript

REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ® , expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Webcast today at 8:00 a.m. ET ROCKVILLE, Md.

news source

PRNewsWire • Nov 5, 2026

news preview

Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates

Regenxbio (RGNX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to a loss of $1.2 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 4, 2026

news preview

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.

news source

Zacks Investment Research • Nov 4, 2026

news preview

REGENXBIO to Participate in Stifel 2026 Healthcare Conference

ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference.

news source

PRNewsWire • Nov 3, 2026

news preview

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m.

news source

PRNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in REGENXBIO Inc.

Open an M1 investment account to buy and sell REGENXBIO Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RGNX on M1